Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmet Yildirim

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Journal of Immunotherapy and Precision Oncology|January 15, 2025
Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution ExperienceTony Z Zhuang, Subir Goyal, Katherine B Case, et al.
Medicina (Kaunas, Lithuania)|May 4, 2026
Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World StudyFatih Yıldız, Berkan Karabuga, Salih Karatlı, et al.
In Vivo (Athens, Greece)|June 30, 2026
Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter StudyBerkan Karabuga, Mustafa Büyükkör, Cengiz Karaçin, et al.
The Oncologist|January 6, 2026
An Increase in Splenic Volume After First-Line Immunotherapy is Associated with Worse PFS in Patients with Metastatic Renal Cell CarcinomaGregory Palmateer, Ahmet Yildirim, Taylor Goodstein, et al.
Frontiers in Oncology|February 16, 2026
Case Report: Looks can deceive: acute postoperative progressive renal dysfunction and hyperkalemia without significant hydronephrosisReza Lahiji, Ahmet Yildirim, William Luke, et al.
Therapeutic Advances in Medical Oncology|February 13, 2025
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitorsAhmet Yildirim, Mengting Wei, Yuan Liu, et al.
Urology Practice|June 15, 2026
Contemporary Validation of the Renal Cell Carcinoma Inflammatory Score (RISK) for Preoperative Prognostication in Non-Metastatic Renal Cell CarcinomaAdam Braunschweig, Gabriel Ekene Agu, Reza Lahiji, et al.
Acta Medica (Hradec Kralove)|April 26, 2017
Common Mistakes in the Dual-Energy X-ray Absorptiometry (DXA) in Turkey. A Retrospective Descriptive Multicenter StudyAli Yavuz Karahan, Bugra Kaya, Banu Kuran, et al.
Annals of Surgical Oncology|February 3, 2021
The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry StudyAtilla Soran, Lutfi Dogan, Arda Isik, et al.
The Oncologist|June 19, 2025
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimensJeffrey Zhong, Albert Jang, Bashar Abuqayas, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Journal of Immunotherapy and Precision Oncology|January 15, 2025
Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution ExperienceTony Z Zhuang, Subir Goyal, Katherine B Case, et al.
Medicina (Kaunas, Lithuania)|May 4, 2026
Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World StudyFatih Yıldız, Berkan Karabuga, Salih Karatlı, et al.
In Vivo (Athens, Greece)|June 30, 2026
Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter StudyBerkan Karabuga, Mustafa Büyükkör, Cengiz Karaçin, et al.
The Oncologist|January 6, 2026
An Increase in Splenic Volume After First-Line Immunotherapy is Associated with Worse PFS in Patients with Metastatic Renal Cell CarcinomaGregory Palmateer, Ahmet Yildirim, Taylor Goodstein, et al.
Frontiers in Oncology|February 16, 2026
Case Report: Looks can deceive: acute postoperative progressive renal dysfunction and hyperkalemia without significant hydronephrosisReza Lahiji, Ahmet Yildirim, William Luke, et al.
Therapeutic Advances in Medical Oncology|February 13, 2025
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitorsAhmet Yildirim, Mengting Wei, Yuan Liu, et al.
Urology Practice|June 15, 2026
Contemporary Validation of the Renal Cell Carcinoma Inflammatory Score (RISK) for Preoperative Prognostication in Non-Metastatic Renal Cell CarcinomaAdam Braunschweig, Gabriel Ekene Agu, Reza Lahiji, et al.
Acta Medica (Hradec Kralove)|April 26, 2017
Common Mistakes in the Dual-Energy X-ray Absorptiometry (DXA) in Turkey. A Retrospective Descriptive Multicenter StudyAli Yavuz Karahan, Bugra Kaya, Banu Kuran, et al.
Annals of Surgical Oncology|February 3, 2021
The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry StudyAtilla Soran, Lutfi Dogan, Arda Isik, et al.
The Oncologist|June 19, 2025
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimensJeffrey Zhong, Albert Jang, Bashar Abuqayas, et al.
Pageof 9